0001193125-24-226538.txt : 20240926 0001193125-24-226538.hdr.sgml : 20240926 20240926084228 ACCESSION NUMBER: 0001193125-24-226538 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240924 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240926 DATE AS OF CHANGE: 20240926 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 241326250 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d841208d8k.htm 8-K 8-K
NASDAQ false 0001369568 0001369568 2024-09-24 2024-09-24

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): September 24, 2024

 

 

CATALYST PHARMACEUTICALS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

 

 

 

Delaware   001-33057   76-0837053
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

355 Alhambra Circle

Suite 801

Coral Gables, Florida

   33134
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (305) 420-3200

Not Applicable

Former Name or Former address, if changed since last report

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

  

Name of Exchange
on Which Registered

  

Ticker
Symbol

Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐    

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01

Other Events

On September 24, 2024, the Company issued a press release announcing that its sub-licensee in Japan, DyDo Pharma, Inc. (“DyDo”), has reported that the Ministry of Health, Labor and Welfare of Japan has approved DyDo’s New Drug Application (“NDA”) to commercialize FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of patients with Lambert-Eaton myasthenic syndrome (“LEMS”) in Japan. Under the sub-license agreement between the Company and DyDo, upon approval of the NDA the Company has earned a milestone payment from DyDo in the amount of JPY 300 million (approximately $2.1 million USD based on current exchange rates).

A copy of the press release is attached hereto as Exhibit 99.1.

 

Item 9.01

Financial Statements and Exhibits.

 (d)    Exhibits

 

99.1    Press release issued by the Company on September 24, 2024
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Catalyst Pharmaceuticals, Inc.
By:  

   /s/ Michael W. Kalb

         Michael W. Kalb
         EVP, Treasurer and CFO

Dated: September 26, 2024

 

3

EX-99.1 2 d841208dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received

Approval to Commercialize FIRDAPSE® in Japan

CORAL GABLES, Fla., September 24, 2024—Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its sub-licensee in Japan, DyDo Pharma, Inc., (“DyDo”) has reported that the Ministry of Health, Labor and Welfare of Japan has approved DyDo’s New Drug Application (“NDA”) to commercialize FIRDAPSE® (amifampridine) Tablets 10 mg for treatment of patients with Lambert-Eaton Myasthenic Syndrome (“LEMS”) in Japan. This approval marks a pivotal advancement in the treatment of LEMS, a rare autoimmune disorder that can severely impact quality of life and represents a significant step forward in addressing the unmet needs of patients affected by LEMS in Japan.

“We are pleased that our partner, DyDo, has secured regulatory approval for FIRDAPSE in Japan. This represents a meaningful milestone, bringing renewed hope to patients and further affirming FIRDAPSE’s proven effectiveness in the treatment of LEMS,” said Richard J. Daly, Catalyst’s President and Chief Executive Officer. “This achievement underscores our unwavering commitment to advancing patient care. We appreciate the collaborative efforts of our partner in securing this approval, and we remain focused on expanding our innovative rare disease product portfolio beyond the U.S. to make a meaningful impact on patients’ lives worldwide.”

FIRDAPSE (amifampridine) is a leading therapy indicated in the United States for the treatment of LEMS in adults and pediatric patients six years of age and older. LEMS is a rare autoimmune disorder characterized by muscle weakness and fatigue. About 50% of people with LEMS have underlying cancer, as LEMS is observed in approximately 3% of small-cell lung cancer patients. FIRDAPSE is the only U.S. FDA-approved, evidence-based treatment for LEMS. As a cornerstone of Catalyst’s commitment to serving those with rare diseases, FIRDAPSE is supported in the U.S. by a comprehensive patient support program to help ensure accessibility and assistance for eligible U.S. patients.

About FIRDAPSE® (amifampridine) Tablets 10 mg

FIRDAPSE® (amifampridine) Tablets 10 mg is an oral, nonspecific, voltage-dependent, potassium (K+) channel blocker that causes depolarization of the presynaptic membrane and slows or inhibits repolarization. This action results in the opening of slow voltage-dependent calcium (Ca2+) channels, allowing for a subsequent influx of Ca2+. In turn, it induces the exocytosis of synaptic vesicles containing acetylcholine (ACh) to release more ACh into the synaptic cleft, enhancing neuromuscular transmission and providing for improved muscle function. Amifampridine phosphate was granted orphan drug designation by the Ministry of Health, Labor, and Welfare in Japan, and FIRDAPSE has previously been approved for use in the U.S. in adults and pediatric patients six years of age and older and in Europe and Canada for the treatment of adults with LEMS.

For Full Prescribing and Safety Information for FIRDAPSE, please visit www.firdapse.com.

About DyDo Pharma

DyDo Pharma is the rare disease pharmaceutical wholly-owned subsidiary of DyDo Group Holdings. DyDo Group Holdings, Inc. operates through the following segments: Domestic Beverage Business, International Beverage Business, Pharmaceutical-related Business, Food Business, and Other Businesses. The Domestic Beverage Business accounts for more than 70% of total sales, and beverages are sold through vending machines that are widely prevalent in Japan. The Company was founded on January 27, 1975, and is headquartered in Osaka, Japan.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst is headquartered in Coral Gables, FL., and was recognized on the Forbes 2024 list as one of America’s most successful small-cap companies. For more information, please visit Catalyst’s website at www.catalystpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including (i) whether DyDo can successfully commercialize FIRDAPSE in Japan, (ii) whether Catalyst’s revenues derived in future periods from its sub-license with DyDo will be profitable and cash flow positive to Catalyst, and (iii) those factors described in Catalyst’s Annual Report on Form 10-K for fiscal year 2023, its Quarterly Report on Form 10-Q for the second quarter of fiscal year 2024, and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.

Investor Relations Contact:

Mary Coleman, Catalyst Pharmaceuticals, Inc.

(305) 420-3200

mcoleman@catalystpharma.com

Media Contact:

David Schull, Russo Partners

(858) 717-2310

david.schull@russopartnersllc.com

EX-101.SCH 3 cprx-20240924.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cprx-20240924_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 cprx-20240924_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Document and Entity Information
Sep. 24, 2024
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001369568
Document Type 8-K
Document Period End Date Sep. 24, 2024
Entity Registrant Name CATALYST PHARMACEUTICALS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-33057
Entity Tax Identification Number 76-0837053
Entity Address, Address Line One 355 Alhambra
Entity Address, Address Line Two Circle
Entity Address, Address Line Three Suite 801
Entity Address, City or Town Coral Gables
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33134
City Area Code (305)
Local Phone Number 420-3200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol CPRX
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports cprx-20240924.xsd cprx-20240924_lab.xml cprx-20240924_pre.xml d841208d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d841208d8k.htm": { "nsprefix": "cprx", "nsuri": "http://www.catalystpharma.com/20240924", "dts": { "schema": { "local": [ "cprx-20240924.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "cprx-20240924_lab.xml" ] }, "presentationLink": { "local": [ "cprx-20240924_pre.xml" ] }, "inline": { "local": [ "d841208d8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-09-24_to_2024-09-24", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d841208d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-09-24_to_2024-09-24", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d841208d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.catalystpharma.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001193125-24-226538-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-226538-xbrl.zip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end XML 17 d841208d8k_htm.xml IDEA: XBRL DOCUMENT 0001369568 2024-09-24 2024-09-24 NASDAQ false 0001369568 8-K 2024-09-24 CATALYST PHARMACEUTICALS, INC. DE 001-33057 76-0837053 355 Alhambra Circle Suite 801 Coral Gables FL 33134 (305) 420-3200 false false false false Common Stock, par value $0.001 per share CPRX false